FDA approves expanded use of BeiGene's blood cancer drug

The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's (6160.HK) combination drug to treat certain patients with a type of blood cancer, the health regulator said on Thursday.